Research Update- BWH Bulletin - For and about the People of Brigham and Women's Hospital
Research Update- BWH Bulletin - For and about the People of Brigham and Women's Hospital
Skip to contents
July 17, 2000
Browse the archive
Current issue
In This Issue:
The Sights and Sounds of Street Beat 2000
Q&A with Patient Care Services VP Nancy Kruger
Research Update
BWH Nurse Launched
Images of Street Beat 2000
Harvard Hospitals and HMS Launch Clinical Research Institute
Partners HealthCare, Harvard Medical School, and CareGroup have forged a comprehensive clinical research partnership—the Harvard Clinical Research Institute (HCRI)—to expand clinical trials across the Harvard medical community. HCRI aims to expand clinical trials in academic health centers, with the highest standard of scientific rigor and protection of patients’ interests. By offering central management for all aspects of research—from efficient and ethical study design to fast and simple patient accrual procedures to expert data analysis—HCRI has been designed to facilitate clinical research by faculty members in affiliated institutions and to provide better access to the faculty for research sponsors from the pharmaceutical and biotechnology industries. The Harvard medical community currently conducts more than $600 million in research each year, of which about $40 million represents industry-sponsored clinical trials. “This new partnership will enhance our ability to contribute to what promises to be a very exciting era in biomedical research,” said Samuel Thier, MD, Partners president and CEO and professor of medicine and health care policy at HMS. “The institute is also a model of how Harvard Medical School and its teaching hospitals can work together to support our key missions in a turbulent health care environment.” James B. Breitmeyer has been named chief executive officer of the new institute. He will manage the overall operations of the not-for-profit corporation and oversee the relationships among participating institutions. He will report to a board of directors composed of 12 members appointed equally by HMS, Partners, and CareGroup. Among the key participating institutions are HMS, Brigham and Women’s Hospital, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. But ultimately, HCRI is expected to be offered to all HMS-affiliated clinical institutions.